SCHEMBL2986285

SCHEMBL2986285

Cc1ccc(C(=O)O[C@@](C(=O)O)(C(=O)c2ccc(C)cc2)[C@@H](O)C(=O)O)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.42
ALDH1A1 P00352 5/20 0.39
LMNA P02545 1/20 0.39
SRD5A2 P31213 1/20 0.39
CA2 P00918 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HPGD P15428 2/20 0.38
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
PPARG P37231 1/20 0.37
PPARA Q07869 1/20 0.37
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37
ADRB3 P13945 1/20 0.37
MAPT P10636 3/20 0.36
CES2 O00748 2/20 0.35
CES1 P23141 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
AKR1C3 P42330 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL72683 1.00 TDP1 (0.42) TDP1ALDH1A1LMNASRD5A2CA2
SCHEMBL27955132 1.00 TDP1 (0.42) TDP1ALDH1A1LMNASRD5A2CA2
SCHEMBL72172 1.00 TDP1 (0.42) TDP1ALDH1A1LMNASRD5A2CA2
SCHEMBL5461407 1.00 TDP1 (0.42) TDP1ALDH1A1LMNASRD5A2CA2
SCHEMBL6532888 1.00 TDP1 (0.42) TDP1ALDH1A1LMNASRD5A2CA2
SCHEMBL88252 1.00 TDP1 (0.42) TDP1ALDH1A1LMNASRD5A2CA2
SCHEMBL7348978 0.99 TDP1 (0.41) TDP1ALDH1A1LMNASRD5A2CA2
SCHEMBL7355024 0.99 TDP1 (0.41) TDP1ALDH1A1LMNASRD5A2CA2
Water SCHEMBL3859938 0.99 TDP1 (0.41) TDP1ALDH1A1LMNASRD5A2CA2
Water SCHEMBL1322825 0.99 TDP1 (0.41) TDP1ALDH1A1LMNASRD5A2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032535-A1 Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof Smith Kline Beecham Corporation D/b/a Glaxo Smith Kline (US) 2007-02-08 US claimed
US-20060058300-A1 Intermediates of bupropion metabolites synthesis SEPRACOR INC. 2006-03-16 US claimed
US-7781427-B2 Process for preparing quinoline compounds and products obtained therefrom WYETH LLC (US) 2010-08-24 US disclosed
US-20100196714-A1 PROCESS FOR PREPARING QUINOLINE COMPOUNDS AND PRODUCTS OBTAINED THEREFROM WYETH (US) 2010-08-05 US disclosed
US-20080281096-A1 Resolution Process For Preparing (+)-2S,3S)-2-(3-Chlorophenyl)-3,3,3-Trimethyl-2-Morpholinol HARRIS MICHAEL ANTHONY 2008-11-13 US disclosed
EP-1807428-A2 PROCESS FOR PREPARING QUINOLINE COMPOUNDS AND PRODUCTS OBTAINED THEREFROM Wyeth (US) 2007-07-18 EP disclosed
US-20070032535-A1 Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof Smith Kline Beecham Corporation D/b/a Glaxo Smith Kline (US) 2007-02-08 US disclosed
EP-1678151-A1 DIASTEREOMERIC DYNAMIC KINETIC RESOLUTION PROCESS FOR PREPARING (+)-(2S, 3S)-2-(3-CHLOROPHENYL)-3,5,5-TRIMETHYL-2-MORPHOLINOL, SALTS, AND SOLVATES THEREOF SMITHKLINE BEECHAM CORPORATION (US) 2006-07-12 EP disclosed
US-20060122385-A1 Process for preparing quinoline compounds and products obtained therefrom WYETH (US) 2006-06-08 US disclosed
WO-2006052768-A2 PROCESS FOR PREPARING QUINOLINE COMPOUNDS AND PRODUCTS OBTAINED THEREFROM WYETH (US) 2006-05-18 WO disclosed
WO-2005044809-A1 DIASTEREOMERIC DYNAMIC KINETIC RESOLUTION PROCESS FOR PREPARING (+)-(2S, 3S)-2-(3-CHLOROPHENYL)-3,5,5-TRIMETHYL-2-MORPHOLINOL, SALTS, AND SOLVATES THEREOF SMITHKLINE BEECHAM CORPORATION (US) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058300-A1 Intermediates of bupropion metabolites synthesis MAOB, MAOA, SLC18A2 TDP1 456/4885ALDH1A1 266/4885LMNA 3466/4885
US-20080281096-A1 Resolution Process For Preparing (+)-2S,3S)-2-(3-Chlorophenyl)-3,3,3-Trimethyl-2-Morpholinol TPMT, MTAP, METTL3 TDP1 2228/4885ALDH1A1 3468/4885LMNA 2155/4885
US-20070032535-A1 Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof METTL3, TPMT, MTAP TDP1 1909/4885ALDH1A1 2670/4885LMNA 2821/4885
US-20060122385-A1 Process for preparing quinoline compounds and products obtained therefrom NNMT, QTRT1, HNMT TDP1 1424/4885ALDH1A1 1820/4885LMNA 1434/4885
US-20100196714-A1 PROCESS FOR PREPARING QUINOLINE COMPOUNDS AND PRODUCTS OBTAINED THEREFROM NNMT, QTRT1, HNMT TDP1 1424/4885ALDH1A1 1820/4885LMNA 1434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.